Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease

Author:

Fudim Marat1,Hopley Charles W.2,Huang Zhen1,Kavanagh Sarah3,Rockhold Frank W.1ORCID,Baumgartner Iris4,Berger Jeffrey S.5,Blomster Juuso I.6,Fowkes F. Gerry R.7,Katona Brian G.8,Mahaffey Kenneth W.9,Norgren Lars10,Ostrom Cara3,Patel Manesh R.1,Jones W. Schuyler1,Hiatt William R.11ORCID

Affiliation:

1. Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, NC (M.F., Z.H., F.W.R., M.R.P., W.S.J.).

2. Department of Medicine, Section of Nephrology and Hypertension, Geisel School of Medicine at Dartmouth College, Hanover, NH (C.W.H.).

3. CPC Clinical Research, Aurora, CO (S.K., C.O.).

4. Swiss Cardiovascular Center, University of Bern, Switzerland (I.B.).

5. Departments of Medicine and Surgery, New York University School of Medicine (J.S.B.).

6. University of Turku, Finland (J.I.B.).

7. University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, United Kingdom (F.G.R.F.).

8. AstraZeneca, Gaithersburg, MD (B.G.K.).

9. Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.W.M.).

10. Orebro University, Faculty of Medicine and Health, Sweden (L.N.).

11. Department of Medicine University of Colorado School of Medicine, Division of Cardiology, and CPC Clinical Research, Aurora (W.R.H.).

Abstract

Background: Current guidelines recommend aggressive management of hypertension. Recent evidence suggested potential harm with low blood pressure targets in patients with peripheral artery disease. We investigated the association of a history of hypertension and office systolic blood pressure (SBP) with major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs). Methods and Results: The EUCLID trial (Examining the Use of Ticagrelor in Peripheral Artery Disease) included 13 885 participants with symptomatic peripheral artery disease; median follow-up was 30 months. Cox proportional hazards regression was used to calculate hazard ratios (HRs) for any MACE, MALE, and MALE including lower extremity revascularization. A clinical history of arterial hypertension was present in 10 857 (78%) participants, and these participants were older and more likely to be female when compared with the 3026 (22%) patients without hypertension. In patients with a history of hypertension, the adjusted hazard ratio for MACE was 0.94, 95% CI, 0.82–1.08; P =0.39, and the adjusted hazard ratio for MALE was 1.08, 95% CI, 0.96–1.23; P =0.21. During follow-up, average SBP was 135 mm Hg (125–145). Every 10 mmHg increase in SBP>125 mmHg was associated with an increased risk of MACE (HR, 1.10 [95% CI, 1.06–1.14]; P <0.001), a marginally increased risk of MALE (HR, 1.07 [95% CI, 1.00–1.15]; P =0.062), and an increased risk of MALE/lower extremity revascularization (HR, 1.08 [95% CI, 1.04–1.11]; P <0.001). Every decrease in 10 mmHg SBP ≤125 mmHg was associated with an increased risk of MACE (HR, 1.19 [95% CI, 1.09–1.31]; P <0.001) but not MALE or MALE/lower extremity revascularization (HR, 1.02 [95% CI, 0.84–1.23], P =0.824; HR, 1.04 [95% CI, 0.95–1.13], P =0.392, respectively). Conclusions: History of hypertension was not associated with higher hazard for MACE or MALE in patients with peripheral artery disease. In contrast, there was a higher hazard of MACE in patients with out-of-target low and high SBP. High but not low SBP was associated with an increased risk of ischemic limb events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01732822.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3